Assenagon Asset Management S.A. Purchases 138,046 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Assenagon Asset Management S.A. grew its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 151.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 229,130 shares of the medical device company's stock after purchasing an additional 138,046 shares during the period. Assenagon Asset Management S.A. owned about 0.48% of AtriCure worth $6,425,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Comerica Bank grew its stake in AtriCure by 70.5% in the first quarter. Comerica Bank now owns 2,522 shares of the medical device company's stock valued at $77,000 after purchasing an additional 1,043 shares in the last quarter. Quest Partners LLC grew its stake in shares of AtriCure by 38.3% in the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company's stock valued at $134,000 after buying an additional 1,626 shares in the last quarter. nVerses Capital LLC increased its holdings in AtriCure by 733.3% during the third quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company's stock worth $140,000 after buying an additional 4,400 shares during the last quarter. Mount Yale Investment Advisors LLC raised its position in AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company's stock worth $222,000 after acquiring an additional 2,368 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in AtriCure by 8.5% in the first quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company's stock valued at $255,000 after acquiring an additional 659 shares during the last quarter. Institutional investors own 99.11% of the company's stock.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded up $0.68 on Tuesday, reaching $29.43. 1,160,700 shares of the company's stock were exchanged, compared to its average volume of 722,135. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.00. The company has a fifty day moving average of $27.35 and a 200-day moving average of $24.26. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -35.94 and a beta of 1.44. The company has a current ratio of 4.13, a quick ratio of 2.93 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). The business had revenue of $116.27 million for the quarter, compared to the consensus estimate of $116.24 million. AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. The firm's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) earnings per share. On average, research analysts predict that AtriCure, Inc. will post -0.77 EPS for the current fiscal year.

Insider Transactions at AtriCure

In related news, Director Maggie Yuen sold 3,500 shares of the business's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $24.07, for a total value of $84,245.00. Following the completion of the transaction, the director now owns 8,970 shares of the company's stock, valued at $215,907.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ATRC has been the topic of several recent analyst reports. JPMorgan Chase & Co. lowered their price objective on shares of AtriCure from $34.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 31st. StockNews.com upgraded AtriCure from a "sell" rating to a "hold" rating in a research note on Saturday, September 14th. Stifel Nicolaus dropped their price target on AtriCure from $30.00 to $26.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Piper Sandler reduced their price objective on shares of AtriCure from $65.00 to $40.00 and set an "overweight" rating for the company in a research report on Wednesday, July 31st. Finally, BTIG Research decreased their price objective on shares of AtriCure from $58.00 to $53.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.44.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.